Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
- 28 August 2014
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 124 (9), 1404-1411
- https://doi.org/10.1182/blood-2014-03-565135
Abstract
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.This publication has 51 references indexed in Scilit:
- Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabBlood, 2011
- Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemiaCancer, 2011
- Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimenBritish Journal of Haematology, 2011
- Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemiaHaematologica, 2011
- IgM Amyloidosis: Clinical Features in Therapeutic OutcomesClinical Lymphoma Myeloma and Leukemia, 2011
- Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and DexamethasoneClinical Lymphoma Myeloma and Leukemia, 2011
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled TrialJournal of Clinical Oncology, 2010
- Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)Leukemia Research, 2010
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaAmerican Journal of Hematology, 2010